Mobile

Avelumab and cetuximab in combination with FOLFOX in patients with previously untreated metastatic colorectal cancer. Avelumab und Cetuximab in Kombination mit FOLFOX bei Patienten mit unbeh...

Update Il y a 4 ans
Reference: EUCTR2016-004434-26

Avelumab and cetuximab in combination with FOLFOX in patients with previously untreated metastatic colorectal cancer. Avelumab und Cetuximab in Kombination mit FOLFOX bei Patienten mit unbehandeltem metastasiertem kolorektalem Karzinom

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

The primary clinical objective is to determine the efficacy of a standard 1st line regimen (FOLFOX and cetuximab) in patients with RAS/BRAF wildtype, MSI or MSS MCRC with avelumab in terms of progression free survival rate after 12 months (acc. to RECIST v1.1).

Inclusion criteria

  • Metastatic colorectal cancer

Links